

1/14

T24 viability: 2nM Gemcitabine + 5 uM SAHA






Figure 18

LNCAP proliferation: 2nM Gemcitabine +/- 5 uM SAHA




LNCAP viability: 2nM Gemcitabine +/- 5 uM SAHA




T24 proliferation: 8 day treatment with 200 nM AZ +/- 5 uM SAHA

time (hours)



T24 cell viability: 8-day treatment with 200 nM AZ +/- 5 uM SAHA






Figure 4A




Figure 4B




Figure 5




Figure 6




Figure 7




Figure 8

B

Percent Inhibition of LNCap Cells Treated with SAHA and Irinotecan




Figure 0

Percent Inhibition of LNCap Cells Treated with SAHA and 5-FU




Figure 10

Percent Inhibition of LNCap Cells Treated with SAHA and Docetaxel




Figure 11